CAMPBELL, Calif.—Nov. 15, 2022—Life sciences solutions company Saama has hired Clinton White, Ph.D., MBA, to serve as Chief Delivery Officer (CDO). Dr. White will oversee Saama’s project delivery teams, helping to scale product development and drive customer success. The appointment is the latest in a series of executive hires to support Saama’s continued growth and commitment to delivering innovative data solutions so that pharmaceutical and biotechnology companies can bring life-changing drugs to market faster.
Dr. White will draw on more than 25 years of experience in clinical research, drug and technology development, operational delivery, and organizational leadership to support the delivery of Saama’s AI-powered clinical data solutions.
“Clinton’s distinguished and diverse range of experience gives him intimate knowledge of what it takes to bring new drugs to market and of the opportunities for technology — like Saama’s — to improve that process,” said Vivek Sharma, CEO of Saama. “But more than that, Clinton’s passion for patients and deep understanding of customer needs will be most valuable in perfecting the delivery of Saama’s existing solutions portfolio and identifying new opportunities for technology to speed clinical trial execution and improve the lives of patients.”
Prior to joining Saama, Dr. White was the global head of oncology project delivery for an industry-leading global contract research organization (CRO). In this role, he managed a large portfolio of phase 1 through phase 3 trials for sponsors ranging from emerging biotech to large pharma.
Before that, he was the Global Head of Enterprise Data and Analytics for another leading global CRO, where he led the company’s big data and next-gen analytics efforts. Dr. White also previously served as Chief Operating Officer for a virtual oncology drug development company conducting pivotal trials in Japan, Asia, Europe, and the U.S., and as a management consultant focused on clinical process improvement, drug development, and asset evaluation.
“Saama is an established clinical technology company well positioned to make material, positive changes to how clinical research is conducted,” said Dr. White. “We have the people, talent, and passion to deliver world-class, innovative solutions that streamline the collection of real-time clinical trial data, generate real-time meaningful clinical insights, and ultimately accelerate the drug development process to help the patients that need it most.”
Dr. White earned a bachelor’s degree in chemistry from the Georgia Institute of Technology, an MBA from the Foster School of Business at the University of Washington, and a Ph.D. in structure-based drug design from the University of Alabama at Birmingham where he was an NIH Pre-Doctoral Fellow. In addition, Clinton completed his post-doctoral training at Caltech where he was named a Gosney Fellow and the Andrew Meadows Fellow of the Damon Runyon-Walter Winchell Cancer Foundation.
He currently resides in Wilmington, North Carolina.
Saama develops life science solutions that accelerate clinical and commercial development. Today, more than 50 biotech companies—including many of the top 20 pharmaceutical companies—use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform to accelerate more than 1,500 studies, including the clinical trial that led to the world’s first COVID-19 vaccine. LSAC’s rich applications facilitate unprecedented and authoritative oversight and automation of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring treatments to patients sooner. Discover more at www.saama.com and follow @SaamaTechInc on Twitter.